| Characteristic . | Overall study population (N = 259) . | VT cycle length >400 ms (N = 89) . | VT cycle length 400–321 ms (N = 82) . | VT cycle length 320–240 ms (N = 78) . | P-value for comparison across groups . |
|---|---|---|---|---|---|
| Age (years) | 68.6 ± 8.1 | 70 ± 6.9 | 67.6 ± 9.3 | 68 ± 8.1 | 0.13 |
| Male sex, no. (%) | 241 (93.1%) | 78 (87.6%) | 78 (95.1%) | 75 (96.2%) | 0.082 |
| Previous PCI, no. (%) | 112 (43.2%) | 39 (43.8%) | 34 (41.5%) | 35 (44.9%) | 0.91 |
| Previous CABG, no. (%) | 118 (45.6%) | 39 (43.8%) | 33 (40.2%) | 41 (52.6%) | 0.27 |
| Diabetes, no. (%) | 77 (29.7%) | 22 (24.7%) | 24 (29.3%) | 27 (34.6%) | 0.39 |
| Hypertension, no. (%) | 180 (69.5%) | 58 (65.2%) | 54 (65.9%) | 60 (76.9%) | 0.2 |
| Chronic kidney disease, no. (%) | 49 (18.9%) | 25 (28.1%) | 9 (11%) | 13 (16.7%) | 0.014 |
| Atrial fibrillation/flutter, no. (%) | 99 (38.2%) | 37 (41.6%) | 27 (32.9%) | 32 (41%) | 0.44 |
| NYHA class, no. (%) | |||||
| I | 61 (23.6%) | 19 (21.3%) | 21 (25.6%) | 19 (24.4%) | 0.32 |
| II | 137 (52.9%) | 44 (49.4%) | 48 (58.5%) | 39 (50%) | |
| III | 61 (23.6%) | 26 (29.2%) | 13 (15.9%) | 20 (25.6%) | |
| Ejection fraction (%) | 28.8 ± 10 | 28.9 ± 9.6 | 28.1 ± 10.6 | 29.4 ± 10 | 0.82 |
| CRT defibrillator, no. (%) | 51 (19.7%) | 22 (24.7%) | 11 (13.4%) | 17 (21.8%) | 0.24 |
| Antiarrhythmic drug at qualification, no. (%) | |||||
| Amiodarone | 169 (65.3%) | 73 (82%) | 49 (59.8%) | 42 (53.8%) | 0.0002 |
| Other medication | 90 (34.7%) | 16 (18.0%) | 33 (40.2%) | 36 (46.2%) | |
| NT-proBNP (pg/mL) | 548 (274–1270) | 798 (280–1594) | 432 (243–1069) | 532 (242–1310) | 0.14 |
| Characteristic . | Overall study population (N = 259) . | VT cycle length >400 ms (N = 89) . | VT cycle length 400–321 ms (N = 82) . | VT cycle length 320–240 ms (N = 78) . | P-value for comparison across groups . |
|---|---|---|---|---|---|
| Age (years) | 68.6 ± 8.1 | 70 ± 6.9 | 67.6 ± 9.3 | 68 ± 8.1 | 0.13 |
| Male sex, no. (%) | 241 (93.1%) | 78 (87.6%) | 78 (95.1%) | 75 (96.2%) | 0.082 |
| Previous PCI, no. (%) | 112 (43.2%) | 39 (43.8%) | 34 (41.5%) | 35 (44.9%) | 0.91 |
| Previous CABG, no. (%) | 118 (45.6%) | 39 (43.8%) | 33 (40.2%) | 41 (52.6%) | 0.27 |
| Diabetes, no. (%) | 77 (29.7%) | 22 (24.7%) | 24 (29.3%) | 27 (34.6%) | 0.39 |
| Hypertension, no. (%) | 180 (69.5%) | 58 (65.2%) | 54 (65.9%) | 60 (76.9%) | 0.2 |
| Chronic kidney disease, no. (%) | 49 (18.9%) | 25 (28.1%) | 9 (11%) | 13 (16.7%) | 0.014 |
| Atrial fibrillation/flutter, no. (%) | 99 (38.2%) | 37 (41.6%) | 27 (32.9%) | 32 (41%) | 0.44 |
| NYHA class, no. (%) | |||||
| I | 61 (23.6%) | 19 (21.3%) | 21 (25.6%) | 19 (24.4%) | 0.32 |
| II | 137 (52.9%) | 44 (49.4%) | 48 (58.5%) | 39 (50%) | |
| III | 61 (23.6%) | 26 (29.2%) | 13 (15.9%) | 20 (25.6%) | |
| Ejection fraction (%) | 28.8 ± 10 | 28.9 ± 9.6 | 28.1 ± 10.6 | 29.4 ± 10 | 0.82 |
| CRT defibrillator, no. (%) | 51 (19.7%) | 22 (24.7%) | 11 (13.4%) | 17 (21.8%) | 0.24 |
| Antiarrhythmic drug at qualification, no. (%) | |||||
| Amiodarone | 169 (65.3%) | 73 (82%) | 49 (59.8%) | 42 (53.8%) | 0.0002 |
| Other medication | 90 (34.7%) | 16 (18.0%) | 33 (40.2%) | 36 (46.2%) | |
| NT-proBNP (pg/mL) | 548 (274–1270) | 798 (280–1594) | 432 (243–1069) | 532 (242–1310) | 0.14 |
ATP, anti-tachycardia pacing; CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter-defibrillator; NTproBNP, N-terminal pro-hormone brain natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; VT, ventricular tachycardia.
| Characteristic . | Overall study population (N = 259) . | VT cycle length >400 ms (N = 89) . | VT cycle length 400–321 ms (N = 82) . | VT cycle length 320–240 ms (N = 78) . | P-value for comparison across groups . |
|---|---|---|---|---|---|
| Age (years) | 68.6 ± 8.1 | 70 ± 6.9 | 67.6 ± 9.3 | 68 ± 8.1 | 0.13 |
| Male sex, no. (%) | 241 (93.1%) | 78 (87.6%) | 78 (95.1%) | 75 (96.2%) | 0.082 |
| Previous PCI, no. (%) | 112 (43.2%) | 39 (43.8%) | 34 (41.5%) | 35 (44.9%) | 0.91 |
| Previous CABG, no. (%) | 118 (45.6%) | 39 (43.8%) | 33 (40.2%) | 41 (52.6%) | 0.27 |
| Diabetes, no. (%) | 77 (29.7%) | 22 (24.7%) | 24 (29.3%) | 27 (34.6%) | 0.39 |
| Hypertension, no. (%) | 180 (69.5%) | 58 (65.2%) | 54 (65.9%) | 60 (76.9%) | 0.2 |
| Chronic kidney disease, no. (%) | 49 (18.9%) | 25 (28.1%) | 9 (11%) | 13 (16.7%) | 0.014 |
| Atrial fibrillation/flutter, no. (%) | 99 (38.2%) | 37 (41.6%) | 27 (32.9%) | 32 (41%) | 0.44 |
| NYHA class, no. (%) | |||||
| I | 61 (23.6%) | 19 (21.3%) | 21 (25.6%) | 19 (24.4%) | 0.32 |
| II | 137 (52.9%) | 44 (49.4%) | 48 (58.5%) | 39 (50%) | |
| III | 61 (23.6%) | 26 (29.2%) | 13 (15.9%) | 20 (25.6%) | |
| Ejection fraction (%) | 28.8 ± 10 | 28.9 ± 9.6 | 28.1 ± 10.6 | 29.4 ± 10 | 0.82 |
| CRT defibrillator, no. (%) | 51 (19.7%) | 22 (24.7%) | 11 (13.4%) | 17 (21.8%) | 0.24 |
| Antiarrhythmic drug at qualification, no. (%) | |||||
| Amiodarone | 169 (65.3%) | 73 (82%) | 49 (59.8%) | 42 (53.8%) | 0.0002 |
| Other medication | 90 (34.7%) | 16 (18.0%) | 33 (40.2%) | 36 (46.2%) | |
| NT-proBNP (pg/mL) | 548 (274–1270) | 798 (280–1594) | 432 (243–1069) | 532 (242–1310) | 0.14 |
| Characteristic . | Overall study population (N = 259) . | VT cycle length >400 ms (N = 89) . | VT cycle length 400–321 ms (N = 82) . | VT cycle length 320–240 ms (N = 78) . | P-value for comparison across groups . |
|---|---|---|---|---|---|
| Age (years) | 68.6 ± 8.1 | 70 ± 6.9 | 67.6 ± 9.3 | 68 ± 8.1 | 0.13 |
| Male sex, no. (%) | 241 (93.1%) | 78 (87.6%) | 78 (95.1%) | 75 (96.2%) | 0.082 |
| Previous PCI, no. (%) | 112 (43.2%) | 39 (43.8%) | 34 (41.5%) | 35 (44.9%) | 0.91 |
| Previous CABG, no. (%) | 118 (45.6%) | 39 (43.8%) | 33 (40.2%) | 41 (52.6%) | 0.27 |
| Diabetes, no. (%) | 77 (29.7%) | 22 (24.7%) | 24 (29.3%) | 27 (34.6%) | 0.39 |
| Hypertension, no. (%) | 180 (69.5%) | 58 (65.2%) | 54 (65.9%) | 60 (76.9%) | 0.2 |
| Chronic kidney disease, no. (%) | 49 (18.9%) | 25 (28.1%) | 9 (11%) | 13 (16.7%) | 0.014 |
| Atrial fibrillation/flutter, no. (%) | 99 (38.2%) | 37 (41.6%) | 27 (32.9%) | 32 (41%) | 0.44 |
| NYHA class, no. (%) | |||||
| I | 61 (23.6%) | 19 (21.3%) | 21 (25.6%) | 19 (24.4%) | 0.32 |
| II | 137 (52.9%) | 44 (49.4%) | 48 (58.5%) | 39 (50%) | |
| III | 61 (23.6%) | 26 (29.2%) | 13 (15.9%) | 20 (25.6%) | |
| Ejection fraction (%) | 28.8 ± 10 | 28.9 ± 9.6 | 28.1 ± 10.6 | 29.4 ± 10 | 0.82 |
| CRT defibrillator, no. (%) | 51 (19.7%) | 22 (24.7%) | 11 (13.4%) | 17 (21.8%) | 0.24 |
| Antiarrhythmic drug at qualification, no. (%) | |||||
| Amiodarone | 169 (65.3%) | 73 (82%) | 49 (59.8%) | 42 (53.8%) | 0.0002 |
| Other medication | 90 (34.7%) | 16 (18.0%) | 33 (40.2%) | 36 (46.2%) | |
| NT-proBNP (pg/mL) | 548 (274–1270) | 798 (280–1594) | 432 (243–1069) | 532 (242–1310) | 0.14 |
ATP, anti-tachycardia pacing; CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter-defibrillator; NTproBNP, N-terminal pro-hormone brain natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; VT, ventricular tachycardia.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
